Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects

Background The role of amylin, which is cosecreted together with insulin by the pancreatic B‐cells, in the pathogenesis of type‐2 diabetes is still unclear. To elucidate a possible relation between amylin and glucagon we directly evaluated the respective prehepatic secretions following administration of a 75‐g oral glucose load (OGL) in humans.

[1]  B. Desbuquois,et al.  Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays. , 1971, The Journal of clinical endocrinology and metabolism.

[2]  L. Rowell,et al.  INDOCYANINE GREEN CLEARANCE AND ESTIMATED HEPATIC BLOOD FLOW DURING MILD TO MAXIMAL EXERCISE IN UPRIGHT MAN. , 1964, The Journal of clinical investigation.

[3]  T. Rink,et al.  Dose-response for glucagonostatic effect of amylin in rats. , 1997, Metabolism: clinical and experimental.

[4]  G. Springer,et al.  Blood group isoantibody stimulation in man by feeding blood group-active bacteria. , 1969, The Journal of clinical investigation.

[5]  T. Adrian,et al.  Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[6]  B. Ludvik,et al.  Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans , 2004, Diabetologia.

[7]  K Thomaseth,et al.  Distribution and kinetics of amylin in humans. , 1998, American journal of physiology. Endocrinology and metabolism.

[8]  T. Rink,et al.  Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin , 1995, Diabetologia.

[9]  B. Ludvik,et al.  Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus , 1990, The Lancet.

[10]  K. Alberti,et al.  The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. , 1999, Metabolism: clinical and experimental.

[11]  A. Cummins.  Absorption of glucose and methionine from the human intestine; the influence of the glucose concentration in the blood and in the intestinal lumen. , 1952, The Journal of clinical investigation.

[12]  C. Gravholt,et al.  Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[13]  R. Silvestre,et al.  Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas , 1990, Regulatory Peptides.

[14]  R. Unger,et al.  Glucagon antibodies and an immunoassay for glucagon. , 1961, The Journal of clinical investigation.

[15]  J. Akram,et al.  Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[16]  D. Steiner,et al.  The metabolism of proinsulin and insulin by the liver. , 1972, The Journal of clinical investigation.

[17]  J. Olefsky.  Lilly Lecture 1980: Insulin Resistance and Insulin Action: An In Vitro and In Vivo Perspective , 1981, Diabetes.

[18]  G. Paxinos,et al.  In vitro autoradiographic localization of amylin binding sites in rat brain , 1994, Neuroscience.

[19]  K Thomaseth,et al.  Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. , 2001, American journal of physiology. Endocrinology and metabolism.

[20]  H. Oie,et al.  Cytosolic Insulin-degrading Activity in Islet-derived Tumor Cell Lines and in Normal Rat Islets , 1985, Diabetes.

[21]  S. Dinneen,et al.  The Postprandial State: Mechanisms of Glucose Intolerance , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[22]  S. Gasic,et al.  Contribution of Splanchnic and Peripheral Vascular Tissues to the Disposal of Angiotensin‐II and to Regional Conversion Rates of Angiotensin‐I: A Pilot Study in Humans , 1991, Journal of cardiovascular pharmacology.

[23]  G. Pacini,et al.  Amylin Release During Oral Glucose Tolerance Test , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[24]  D. W. Hayden,et al.  Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K Thomaseth,et al.  Integrated mathematical model to assess beta-cell activity during the oral glucose test. , 1996, The American journal of physiology.

[27]  M. Ellenberg,et al.  Diabetes mellitus: theory and practice , 1970 .

[28]  F. Féry,et al.  Glucose Metabolism During the Starved-To-Fed Transition in Obese Patients With NIDDM , 1994, Diabetes.

[29]  H. Kuzuya,et al.  Characterization of Seven C-peptide Antisera , 1978, Diabetes.

[30]  Michael W. Schwartz,et al.  Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells , 1990, Diabetes.

[31]  X. Ding,et al.  Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. , 1999, The American journal of physiology.

[32]  R. Rizza,et al.  Contribution to Postprandial Hyperglycemia and Effect on Initial Splanchnic Glucose Clearance of Hepatic Glucose Cycling in Glucose-Intolerant or NIDDM Patients , 1991, Diabetes.

[33]  B. Ludvik,et al.  Decrease of Stimulated Amylin Release Precedes Impairment of Insulin Secretion in Type II Diabetes , 1991, Diabetes.